For the treatment of constipation
  • Sodium picosulfate is a locally acting laxative from the triarylmethane group, which after bacterial cleavage in the colon, stimulates bowel movements and promotes accumulation of water, and consequently electrolytes, in the colonic lumen.This results in a stimulation of defecation, reduction of transit time and softening of the stool.
  • It is usually effective within 6 to 12 hours.

Each 1 ml of Laxonil® drops contains:

  • Sodium picosulfate    7.5 mg

Laxonil® drops is used in the following cases:

  • For the treatment of constipation.
  • Bowel evacuation before abdominal radiolog- ical and endoscopic procedures on the colon, and surgery.
  • Laxonil® drops is contraindicated in patients  with ileus, intestinal obstruction, acute abdo-  minal conditions like acute appendicitis, acute inflammatory bowel diseases, and severe  abdominal pain associated with nausea and  vomiting which may be indicative of the aforementioned severe conditions.
  • Severe dehydration and when symptoms of water and electrolyte disturbances such as fatigue, weakness, muscle cramps, thirst, dizziness and fainting, are present.
  • Patients with known hypersensitivity to sodium picosulfate.
  • Laxonil® drops should only be taken during pregnancy on medical advice.
  • Laxonil® drops can be safely used during breast-feeding.
  • Gastrointestinal disorders: such as abdominal cramps, abdominal pain, diarrhoea, vomiting, nausea, abdominal discomfort.
  • Dizziness and syncope: ocurring after taking sodium picosulfate appear to be consistent with a vasovagal response (e.g., to abdominal spasm, defecation.)  
  • Children 2 to 4 years: 7 drops at night.
  • Children 4 to 10 years: 7 to 14 drops at night.
  • Adults and children over 10 years: Initially 14 drops at night and can be increased up to 27 drops only if required.
  • Children should not take Laxonil® without medical advice.
  • Patients with renal or cardiac impairment, or dehydration, should consult a physician before taking Laxonil® drops.
  • As with all laxatives, Laxonil® drops should not be taken on a continuous daily basis or for extended periods, without investigating the cause of constipation. Prolonged or excessive use may lead to excessive water loss, electrolyte imbalance and hypokalaemia.
  • Laxonil® drops, as with other laxatives, when taken in chronic overdose may cause diarrhoea, abdominal pain, hypokalaemia, secondary hyperaldosteronism and renal calculi. Renal tubular damage, metabolic alkalosis and muscle weakness secondary to hypokalaemia have also been described in association with chronic laxative abuse.
  • Bottle of 15 ml oral drops with standard dropper.
  • Store at temperature not exceeding 25° C.